archive-com.com » COM » O » ONCGNOSTICS.COM

Total: 361

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Order | oncgnostics GmbH
    below Order GynTect here Title Mr Mrs Dr Name Company Organization E Mail number of items article GynTect Kit 6 assays Bisulfite Kit Swab Set Flyer physicians labs delivery date number of items article GynTect Kit 6 assays Bisulfite Kit Swab Set Flyer physicians labs delivery date number of items article GynTect Kit 6 assays Bisulfite Kit Swab Set Flyer physicians labs delivery date number of items article GynTect Kit 6 assays Bisulfite Kit Swab Set Flyer physicians labs delivery date Recipient Delivery address No Postal code City Notes Information for patients Cervical cancer Cervical cancer diagnostics What is GynTect doing More information Contact FAQ patients Information for physicians GynTect test procedure Screening algorithm Trial data FAQ physicians Order Information for diagnostic laboratories Test principle Screening algorithm Trial data FAQ Labs Order Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive notifications of new posts by email Enter your Email Adress Our Topics GynTect

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-physicians/order/?lang=en (2016-02-15)
    Open archived version from archive


  • Information for diagnostic laboratories | oncgnostics GmbH
    employed especially for the clarification of abnormal findings in the Pap smear such as Pap III or Pap IIID or in case of a positive HPV test result Thus GynTect may be recommended to the gynecologist and the patient if they want support in the decision if a surgery is already necessary GynTect is an easy to perform test which can be performed in molecular diagnostic tests without specific requirements You may find the test principle here Information for patients Cervical cancer Cervical cancer diagnostics What is GynTect doing More information Contact FAQ patients Information for physicians GynTect test procedure Screening algorithm Trial data FAQ physicians Order Information for diagnostic laboratories Test principle Screening algorithm Trial data FAQ Labs Order Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive notifications of new posts by email Enter your Email Adress Our Topics GynTect Cervical cancer Information for patients Information for physicians Information for diagnostic laboratories

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-diagnostics-laboratories/?lang=en (2016-02-15)
    Open archived version from archive

  • Screening algorithm | oncgnostics GmbH
    women with abnormal cytology findings Pap III Pap IIID those who have or develop a precancerous lesion or cancer In case of a negative GynTect result watchful waiting is recommended for the patient during which the HPV test should be repeated in order to check if the infection disappears If the HPV infection remains GynTect needs to be repeated as well Click on the video below for watching this screening scheme Information for patients Cervical cancer Cervical cancer diagnostics What is GynTect doing More information Contact FAQ patients Information for physicians GynTect test procedure Screening algorithm Trial data FAQ physicians Order Information for diagnostic laboratories Test principle Screening algorithm Trial data FAQ Labs Order Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive notifications of new posts by email Enter your Email Adress Our Topics GynTect Cervical cancer Information for patients Information for physicians Information for diagnostic laboratories Investors contact Recent Posts Greiner Bio

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-diagnostics-laboratories/screening-algorithm/?lang=en (2016-02-15)
    Open archived version from archive

  • FAQ Labs | oncgnostics GmbH
    kit required for this chemical treatment from the GynTect distributor For the performance of the bisulfite treatment you need a heating block with cooling option e g a simple thermocycler with a block for 0 5 ml reaction tubes The GynTect assay currently is established on the realtime PCR platforms Abi7300 and Abi7500 Life Technologies Back to Index How long does it take to get a GynTect test result GynTect can be performed within one lab working day independent of the number of tests performed in parallel The hands on time which includes sample preparation 10 min prior to the bisulfite treatment and a purification 30 min after this chemical treatment as well as the set up of the PCR reaction 10 30 min depending upon the number of samples is readily comprehensible At the end of the PCR run max 30 min are required for the evaluation of the results Back to Index Which controls are included in a GynTect run A GynTect assay for a patient sample includes two internal controls 1 the detection of a DNA fragment which only functions if the sample material after bisulfite treatment is of sufficient quality and quantity this fragment does not contain methylated bases 2 the detection of a methylated DNA fragment which indicates that the methylation of the DNA has remained stable during sample transport and preparation Back to Index Information for patients Cervical cancer Cervical cancer diagnostics What is GynTect doing More information Contact FAQ patients Information for physicians GynTect test procedure Screening algorithm Trial data FAQ physicians Order Information for diagnostic laboratories Test principle Screening algorithm Trial data FAQ Labs Order Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-diagnostics-laboratories/faq-labs/?lang=en (2016-02-15)
    Open archived version from archive

  • For Investors / Partners | oncgnostics GmbH
    Jobs News Blog Search Investors and partners oncgnostics develops based on proprietary epigenetic biomarkers highly reliable in vitro diagnostic tests for screening therapeutic decisions and follow up care in cancer diagnostics oncgnostics is therefore active in a market which currently shows 2 digit growth rates Reorganizations in the field of cervical cancer screening in several European countries will provide very attractive market opportunities for our first product GynTect Have we evoked your interest Please contact us by phone or email Press Events Talks Professional opinions statements Investors and partners Investors contact Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive notifications of new posts by email Enter your Email Adress Our Topics GynTect Cervical cancer Information for patients Information for physicians Information for diagnostic laboratories Investors contact Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable

    Original URL path: http://www.oncgnostics.com/for-investors-partners/?lang=en (2016-02-15)
    Open archived version from archive

  • Press | oncgnostics GmbH
    purpose the internationally active company had closed a marketing and distribution partnership with oncgnostics GmbH who has developed and produces the GynTect test prior to Medica 2015 Read more oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement 18 November 2015 in Press Releases by Martina Schmitz Read more Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect 18 September 2015 in Press Releases by TowerPR Jena Germany September 18th 2015 A new test for use in cervical cancer screening is CE IVD marked in whole Europe with immediate effect It may quickly yield reliable test results which will allow to identify more cancer cases early and thus to yield better therapy outcome Developed by the biotech startup oncgnostics www oncgnostics com GynTect Read more Press Events Talks Professional opinions statements Investors and partners Investors contact Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive

    Original URL path: http://www.oncgnostics.com/for-investors-partners/press/?lang=en (2016-02-15)
    Open archived version from archive

  • Events / Talks | oncgnostics GmbH
    Labs Order For Investors Partners Press Events Talks Professional opinions statements Investors and partners Investors contact About oncgnostics About us Management Lab team Advisory board History Pipeline Ovarian cancer Head and neck cancer Access Contact Press Jobs News Blog Search Events and Talks Press Events Talks Professional opinions statements Investors and partners Investors contact Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive notifications of new posts by email Enter your Email Adress Our Topics GynTect Cervical cancer Information for patients Information for physicians Information for diagnostic laboratories Investors contact Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Show all Events Contact oncgnostics GmbH BioInstrumentezentrum Jena Winzerlaer Str 2 07745 Jena Germany oncgnostics GmbH The oncgnostics GmbH a spin off

    Original URL path: http://www.oncgnostics.com/for-investors-partners/events-talks/?lang=en (2016-02-15)
    Open archived version from archive

  • Professional opinions / statements | oncgnostics GmbH
    biology university hospital Heidelberg and co founder of mtm laboratories GmbH oncgnostics has identified and clinically validated its patented biomarkers which may be used in various fields in cancer diagnostics This allows strategic partners from the pharma and diagnostics field the access to innovative and reliable tests in a growth market Oliver Schacht PhD CEO Curetis AG co founder of Epigenomics AG With GynTect patients quickly and reliably receive certainty in the clarification of unclear Pap and HPV results Thus the test may help to avoid unnecessary invasive diagnostics and treatment and reduce costs in health economy Prof Dr Matthias W Beckmann Director women s hospital University Hospital Erlangen Coordinator S3 guideline cervical carcinoma and Chairman of the guideline commission of the German society for Gynaecology Obstetrics DGGG Press Events Talks Professional opinions statements Investors and partners Investors contact Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive notifications of new posts by email

    Original URL path: http://www.oncgnostics.com/for-investors-partners/professional-opinions-statements/?lang=en (2016-02-15)
    Open archived version from archive



  •